Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod versus surgery for low-risk basal cell carcinoma
ACTRN12611001083987Phase 3Active, not recruiting
- Sponsor
- University of Nottingham
- Start
- Jun 2003
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in basal cell carcinoma (BCC) (2 arms), sponsored by University of Nottingham. Primary endpoint: Treatment success at 3 years. Started Jun 2003; status: active, not recruiting.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on ACTRN12611001083987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001083987.